

Plenary Session

SUNDAY, SEPTEMBER 15, 2019 | Plenary Session | 8:00 – 9:30 AM

To Infinity & Beyond! The Expanding Roles of Data Sharing & Collaboration

DEVELOPMENT TRACK

Offers both CME & CPE Credit

UAN #0238-0000-19-021-L01-P

ACPE – 1.5 CONTACT HOURS/KNOWLEDGE-BASED

CO-PRESENTERS:

Jeffrey S. Barrett, PhD, Head, Bill & Melinda Gates Medical Research Inst, Quantitative Sciences

John F. Crowley, JD, MBA, Chairman of the Board & Chief Executive Officer, Amicus Therapeutics Inc

TARGET AUDIENCE:

This Plenary Session will be useful for clinical pharmacologists working in academic, pharmaceutical industry or regulatory settings.

GOALS & OBJECTIVES:

Following the completion of this activity, the learner will be able to:

1. State how both drug development and clinical therapeutics may change over the next 50 years and how the pharmaceutical industry, regulators, private foundations and the healthcare system will contribute to that change;
2. Recall several ways in which the discipline of clinical pharmacology will need to adapt to meet the changing drug development and therapeutic landscape over the next five decades;
3. Articulate the main barriers to the development of effective and safe therapies for rare diseases;
4. Give several examples of how developers, regulators, payers and funding can contribute toward a viable and sustainable model for the development of therapies for rare diseases.



Jeffrey S. Barrett, PhD

[See Dr Barrett's bio.](#)



John F. Crowley, JD, MBA

[See Mr Crowley's bio.](#)